Skip to main content
SpringerLink
Log in

The role of immunotherapy in urologic malignancies

  • Chapter
Diagnosis and Treatment of Genitourinary Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR,volume 88))

Abstract

A proposed mechanism for the progression of cancer is the failure or overwhelming of the immune surveillance system[1]. That some form of immune recognition does indeed occur against malignant cells in patients has been shown by numerous investigators [2–7]. Our inability to effectively manipulate the immune response against neoplasia represents more a lack of knowledge about immune antitumor interactions than a lack of antitumor immunity. Immunotherapeutic strategies for the treatment of cancer include both active and passive approaches. Active immunotherapy can be achieved by immunizing the host against either tumor, modified tumor, or tumor-associated antigens. The passive approach includes monoclonal antibody therapy, the transfer to the host of sensitized cells capable of mediating antitumor responses, and administration of various cytokines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wanderlich JR, Hodes RJ (1991). Biology of cellular immune response. In DeVitta VT, Hellman S, Rosenberg SA (eds), Biologic Therapy of Cancer. JB Lippincott: Philadelphia, pp. 3–21.

    Google Scholar 

  2. Klein G, Clifford P, Kleing E, Stjernsward J (1996). Search for tumor specific immune reactions in Burkitt’s lymphoma patients by membrane immunofluorescence reaction. Proc Natl Acad Sci USA 55:1628–1635.

    Article  Google Scholar 

  3. Morton DL, Malmgren RA, Holmes EC, Ketcham AS (1968). Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233–240.

    PubMed  CAS  Google Scholar 

  4. Morton DL, Malgren RA (1968). Human osteosarcomas: immunologic evidence suggesting an associated infection agent. Science 162:1279–1281.

    Article  PubMed  CAS  Google Scholar 

  5. Sjögren Ho, Hellstromöm I, Bansal SC (1972). Elution of ‘blocking factors’ from human tumors capable of abrogating tumor cell destruction by specifically immune lymphocytes. Int J Cancer 9:274–283.

    Article  PubMed  Google Scholar 

  6. Hellström I, Hellström KE (1983). Cell-mediated reactivity to human tumor-type associated antigens: does it exist? J Biol Response Mod 2:310–320.

    PubMed  Google Scholar 

  7. Vanky F, Klein E (1982). Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T-lymphocytes. Int J Cancer 29:547–553.

    Article  PubMed  CAS  Google Scholar 

  8. Kurzrock R, Gutterman Ju, Talpaz M (1991). Interferons α, β, γ. basic principles and preclinical studies. In Devitta VT, Hellman S, Rosenberg SA (eds), Biologic Therapy of Cancer. Philadelphia: JB Lippincott, pp. 247–274.

    Google Scholar 

  9. Quesade JR, Swanson DA, Trindade A, Gutterman JU (1983). Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43:940–947.

    Google Scholar 

  10. DeKernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983). The treatment of renal cell carcinoma with human leukocyte alpha interferon. J Urol 130:1063–1066.

    Google Scholar 

  11. Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, Ernstoff MS, Gordon L, Lutes R, Bonomi P, Lytton B, Coblieigh M, Taylor SJ IV (1985). A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society Collaborative Trial. Cancer Res 45:863–871.

    PubMed  CAS  Google Scholar 

  12. Quesada JR, Rios A, Swanson D, Trown P, Guttermon JU (1985). Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522–1528.

    PubMed  CAS  Google Scholar 

  13. Umeda T, Niijima T (1988). Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 58:231–235.

    Google Scholar 

  14. Vugrin D, Hood L, Taylor W, Laszlo J (1985). Phase II study of human lymphoblastoid interferon in patients with advanced renal cell carcinoma. Cancer Treat Rep 69:817–820.

    PubMed  CAS  Google Scholar 

  15. Stahl M, Wilke H-J, Seeber S, Schmoll HJ (1992). Cytokins and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 19:70–79.

    PubMed  CAS  Google Scholar 

  16. Reinhart J, Malspeis Z, Young D, Neidhart J (1986) Phase I/II trial of human recombinant beta interferon serine in patients with renal cell carcinoma. Cancer Res 46:5364–5367.

    Google Scholar 

  17. Recombinant human interferon gamma (5-6810), Research group on renal cell carcinoma (1987). Phase II study of recombinant human interferon gamma (5-6810) on renal cell carcinoma. Cancer 60:929–933.

    Article  Google Scholar 

  18. Garnick MB, Reich SD, Maxwell B, Coval-Godsmith S, Richie JP, Rudnick SA (1988). Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 139:251–258.

    PubMed  CAS  Google Scholar 

  19. Quesada JR (1989). Role of interferons in the therapy of metastatic renal cell carcinoma. Urology 34:80–83.

    Article  PubMed  CAS  Google Scholar 

  20. Rosenberg SA (1993). Principles and applications of biologic therapy. In Devitta VT, Hellman S, Rosenberg SA (eds), Cancer: Principles & Practice of Oncology. JB Lippincott: Philadelphia, pp. 293–324.

    Google Scholar 

  21. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghaussen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985). Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492.

    Article  PubMed  CAS  Google Scholar 

  22. Rosenberg SA, Lotze MT, Mmul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT (1987). Patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2. alone. N Engl J Med 316:889–897.

    Article  PubMed  CAS  Google Scholar 

  23. Rosenberg SA, Yang JC, Topalian SI, Schwartzent, Ruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. JAMA 271:907–913.

    Article  PubMed  CAS  Google Scholar 

  24. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J (1991). Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 9:2110–2119.

    PubMed  CAS  Google Scholar 

  25. Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987). In-vivo and in-vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 5:1933–1937.

    PubMed  CAS  Google Scholar 

  26. Whitehead WP, Ward D, Hemingway L, Hemstreet GP III, Bradley E, Konrad M (1990). Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell carcinoma. Cancer Res 50:6708–6715.

    PubMed  CAS  Google Scholar 

  27. Marumo K, Muraki J, Ueno M, Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H (1989). Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 33:219–225.

    Article  PubMed  CAS  Google Scholar 

  28. Lissoni P, Barnis, Ardizzoia A, Crispino S, Paolorossi F, Archiii C, Vaghi M, Tancini G (1992). Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:92–96.

    Article  PubMed  CAS  Google Scholar 

  29. Sleijer D, TH, Janssen RAJ, Buter J, DeVries EGE, Willense PHB, Mulder NH (1992). Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119–1123.

    Google Scholar 

  30. Stoter G, Fossa SD, Rugarli C, Symann M, Jasmin C, Israel L, Bijman JT, Palmer P, Franks CR, Philip T (1989). Metastatic renal cell cancer treated with low-dose interleukin-2. A phase II multicentre study. Cancer Treat Rev 16(Suppl A):111–113.

    Article  PubMed  Google Scholar 

  31. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewsik C, Roy SE, Shearer RJ, Marsden RA, Beran D, Gordon-Smith EC, Coombes RC (1991). The clinical effects of prolonged treatment of patients with advanced cancer with low dose subcutaneous interleukin-2. Br J Cancer 63:275–278.

    Article  PubMed  CAS  Google Scholar 

  32. Leahy MG, Pitfield D, Propert S, Gallagher CJ, Oliver RTD (1992). Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration. Eur J Cancer 28A(Suppl):1049–1051.

    Article  PubMed  CAS  Google Scholar 

  33. Yang JC, Tapalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, Rosenberg SA (1994). Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma. An Interim Report. J Clin Oncol 12:1572–1576.

    CAS  Google Scholar 

  34. Cameron RB, Mcintosh JK, Rosenberg SA (1988). Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810–5817.

    PubMed  CAS  Google Scholar 

  35. Schiller JH, Hanh J, Storer B, Borchert AA, Moore KH, Albertini M, Bechhofer R, Wesley O, Brown RR, Bastin AM, Sondel PM (1992). A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon in humans. Cancer Res 53:1286–1292.

    Google Scholar 

  36. Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H (1990). Home therapy with recombinant interleukin-2 and interferon α-2b in advanced human malignancies. Lancet 335:1509–1512.

    Article  PubMed  CAS  Google Scholar 

  37. Mittelman A, Puccio C, Ahmed T, Zeffren J, Choudhury A, Arlin Z (1991). A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma. Cancer 68:1699–1702.

    Article  PubMed  CAS  Google Scholar 

  38. Besana C, Borri A, Bucci E, Citterio G, DiLucca, Fortis C, Matteucci P, Tognella S, Tresoldi M, Baiocchi C, Landonic G, Ghislandi E, Rugarli C (1994). Treatment of advanced renal cell cancer with sequential intravenous recombinat interleukin-2 and subcutaneous α-interferon. Eur J Cancer 30A:1292–1298.

    Article  PubMed  CAS  Google Scholar 

  39. Lipton A, Harvey H, Givant E, Hopper K, Lawler J, Matthews Y, Hirsh M, Zeffren J (1993). Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother 13:122–129.

    Article  CAS  Google Scholar 

  40. Bergmann L, Fenchel K, Weidmann E, Enzinger Hm, Jan B, Jonas D, Mitrou PS (1993). Daily alternating administration of high-dose alpha-2a-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 72:1833–1842.

    Google Scholar 

  41. Ravand A, Negrier S, Cany L, Merrouche Y, LeGuillou M, Blay JY, Clarel M, Gaston R, Oskam R, Phillip T (1994). Subcutaneous low-dose recombinant interleukin-2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69:1111–1114.

    Article  Google Scholar 

  42. Atzpodien J, Lopez Hannienen E, Kirchner H, et al. (1995). Multi-institutional home therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497–501.

    PubMed  CAS  Google Scholar 

  43. Reiter Z, Ozes ON, Blatt LM, Taylor MW (1992). A dual anti-tumor effect of a combination of interferone-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 62:103–111.

    Article  PubMed  CAS  Google Scholar 

  44. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Franzke A, Poliwoda H (1994). European studies of interleukin-2 in metastatic renal cell carcinoma. Proc ASCO 13:247 (abstract #773).

    Google Scholar 

  45. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ (1994). Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9:103–111.

    Article  PubMed  CAS  Google Scholar 

  46. Fisher RI, Coltman CA Jr, Doroshow JH, Rayner A, Hawkins MJ, Meir JW, Weirnik P, McMannis JD, Weiss JR, Margolin KA, Gelmo BT, Hoth DF, Parkinson DR, Paletta E (1988). Metastatic renal cell cancer treated with interleukin-2 and lymphokine activated killer cells. A Phase II clinical trial. Ann Inten Med 108:518–523.

    Article  CAS  Google Scholar 

  47. Rosenberg SA, Lotze MT, Yang JC, Topolian JL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE (1993). Prospective randomized trial of high-dose IL-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632.

    Article  PubMed  CAS  Google Scholar 

  48. Oostenwijk E, Debruyne FMJ, Schalken JA (1995). The use of monoclonal antibody G250 in the therapy of renal cell carcinoma. Semin Oncol 22:34–41.

    Google Scholar 

  49. Divgi CR, Bander NH, Welt S, Scott AM, Gulec S, Motzer R, Finn RD, Oosterwijk E, Williams J, Broussard E, Larson SM, Old LJ (1995). Phase I/II trial with 1-131 labelled monoclonal antibody (MAB) G250 in metastatic renal cell cancer (RCC). Proc ASCO 14:423 (abstract #1345).

    Google Scholar 

  50. Morales A, Eidinger D, Bruce AW (1976). Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183.

    PubMed  CAS  Google Scholar 

  51. Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, Melamed MR, Whitmore WF Jr (1988). Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6:1450–1455.

    PubMed  CAS  Google Scholar 

  52. Lamm DL (1985). Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 134:40–46.

    PubMed  CAS  Google Scholar 

  53. Lamm DL, Crawford DL, Crawford ED, Montie JE, Scardino P, Grossman B, Stanisic TH, Smith JA Jr, Sullivan J, Sarsdy MF, Crissman JD, Coltman CA, for the Southwest Oncology Group (1991). A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 325:1205–1209.

    Article  PubMed  CAS  Google Scholar 

  54. Herr HW, Schwalb DM, Ahang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF (1995). Intravesical Bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten year follow-up of a prospective randomized trial. J Clin Oncol 13:1404–1408.

    PubMed  CAS  Google Scholar 

  55. Lamm DL (1992). Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573–580.

    PubMed  CAS  Google Scholar 

  56. Morales A, Nickel JC (1992). Immunotherapy of superficial bladder cancer, a developmental and clinical overview. Urol Clin North Am 19:549–556.

    PubMed  CAS  Google Scholar 

  57. Ratliff TL, Hudson MA, Catalona WJ (1991). Strategy for improving therapy of superficial bladder cancer. World J Urol 9:95.

    Article  Google Scholar 

  58. Becich MJ, Carroll S, Ratliff TL (1991). Internalization of Bacillus Calmette-Gué by bladder tumor cells. J Urol 145:1316–1324.

    PubMed  CAS  Google Scholar 

  59. Prescott S, James K, Hargrave TB, Chisolm GD, Smyth JF (1990). Radioimmune assay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144:1248–1251.

    PubMed  CAS  Google Scholar 

  60. Balbay D, Ozen H, Ozkardes H, Barut A, Bakkaloglu M, Tasar C, Remzi D (1994). Detection of urinary interleukin 2, interleukin 2 receptor, tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy. Urology 43:187–190.

    Article  PubMed  CAS  Google Scholar 

  61. Haaff EO, Dresner SM, Ratliff TL, Catalona WJ (1986). Two courses of intravesical Bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. J Urol 136:820–824.

    PubMed  CAS  Google Scholar 

  62. Kavoussi LR, Terrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner M, Ratliff TL, Catalona WJ (1988). Results of 6 weekly intravesical Cacillus Calmette-Guérin instillation on the treatment of superficial bladder tumors. J Urol 139:935–940.

    PubMed  CAS  Google Scholar 

  63. Lamm DL, Crawford ED, Blumenstein B, Crissman JD, Montie J, Gottesman J, Lowe B, Sarosdy MF, Bohl MF, Weems WL, Grossman HB, Smith JA, Beck TM, Leimert J, Coltman CA (1992). Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J Urol 147:274A (abstract #242).

    Google Scholar 

  64. Herr HW (1991). Progression of T1 bladder tumors after intravesical Bacillus Calmette-Guérin. J Urol 145:40–43.

    PubMed  CAS  Google Scholar 

  65. Morales A, Nickel JC, Wilson JLW (1992). Dose response of BCG in superficial bladder cancer. J Urol 147:1256–1258.

    PubMed  CAS  Google Scholar 

  66. Pagano F, Bast P, Milani C, Meneghini A, Maruzzi D, Garbeglio A (1991). Low dose Bacillus Calmette-Guérin in superficial bladder cancer therapy: is it effective? J Urol 146:32–35.

    PubMed  CAS  Google Scholar 

  67. Mack D, Frick J (1995). Low dose Bacillus Calmette-Guérin (BCG) therapy in superficial high risk bladder cancer a phase II study with the BCG strain Connaught Conade. Br J Urol 75:185–187.

    Article  PubMed  CAS  Google Scholar 

  68. Bast RC Jr, Zbar B, Borsos T, Rapp HJ (1974). BCG and Cancer I. N Engl J Med 290:1413–1420.

    Article  PubMed  Google Scholar 

  69. Lamm DL, Reichert DF, Harris SC, Lucio RM (1982). Immunotherapy of murine transtional cell carcinoma. J Urol 128:1104–1108.

    PubMed  CAS  Google Scholar 

  70. Lamm DL (1992). Superficial bladder cancer, carcinoma in situ. Urol Clin North Am 19:499–509.

    PubMed  CAS  Google Scholar 

  71. Lamm DL (1992). Superficial bladder cancer, long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573–580.

    PubMed  CAS  Google Scholar 

  72. Lamm DL, Griffith JG (1992). Intravesical therapy: does it affect the natural histrory of superficial bladder cancer? (review). Semin Urol 10:39–44.

    PubMed  CAS  Google Scholar 

  73. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A (1991). A low dose Bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J Urol 146:32–35.

    PubMed  CAS  Google Scholar 

  74. Lamm DL, Meijden APM Vander, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A (1992). Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147:596–600.

    PubMed  CAS  Google Scholar 

  75. Lamm DL (1992). Complications of Bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 19:562–572.

    Google Scholar 

  76. Torti F, Shortliffe L, Williams R, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J, Spiegel R, McWhirter K, Freiha F (1988). Alpha interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 6:476–483.

    PubMed  CAS  Google Scholar 

  77. Glashan R (1990). A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder. J Urol 144:658–661.

    PubMed  CAS  Google Scholar 

  78. Olsson CA, Chute R, Rao CN (1974). Immunologic reduction of bladder cancer recurrence rate. J Urol 111:173–176.

    PubMed  CAS  Google Scholar 

  79. Jurincic C, Engelmann U, Gasch J, Klippel KF (1988). Immunotherapy in bladder cancer with Keyhole-Limpet hemocyanin: a randomized study. J Urol 139:723–726.

    PubMed  CAS  Google Scholar 

  80. Flamm J, Bucher A, Holtl W, Albrecht W (1990). Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy: a prospective randomized trial. J Urol 244:260–263.

    Google Scholar 

  81. Rios A, Stringfellow DA, Fitzpatrick FA, Reele SB, Guthnecht GD, Hersh EM (1986). Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer in cancer patients. J Biol Respir Modif 5:330–338.

    CAS  Google Scholar 

  82. Lamm DL (1995). BCG immunotherapy for transitional-cell carcinomal in situ of the bladder. Oncology 9:947–955.

    PubMed  CAS  Google Scholar 

  83. Brinkmann U, Gallo M, Brinkmann E, Kunwar S, Pastan I (1993). A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc Natl Acad Sci USA. 90:547–551.

    Article  PubMed  CAS  Google Scholar 

  84. Moodry DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB (1994). Interleukin-2 trans-fected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24:44–51.

    Google Scholar 

  85. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E (1994). Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765.

    PubMed  CAS  Google Scholar 

  86. Tjota A, Ahang YQ, Piedmonte MR, Lee CL (1991). Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metasteses of syngeneic Dunning rat prostate tumor. J Urol 146: 177–183.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Yousif A. Abubakr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce G. Redman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, 48109-0680, USA

    Kenneth J. Pienta

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abubakr, Y.A., Redman, B.G. (1996). The role of immunotherapy in urologic malignancies. In: Pienta, K.J. (eds) Diagnosis and Treatment of Genitourinary Malignancies. Cancer Treatment and Research, vol 88. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6343-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6343-3_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7913-3

  • Online ISBN: 978-1-4615-6343-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation